Psychology Wiki

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

This article is in need of attention from a psychologist/academic expert on the subject.
Please help recruit one, or improve this page yourself if you are qualified.
This banner appears on articles that are weak and whose contents should be approached with academic caution.

Nootropics (File:Loudspeaker.svg /n.əˈtrɒpɨks/ Template:Respell), also referred to as smart drugs, memory enhancers, neuro enhancers, cognitive enhancers, and intelligence enhancers, are drugs, supplements, nutraceuticals, and functional foods that purportedly improve mental functions such as cognition, memory, intelligence, motivation, attention, and concentration.[1][2] The word nootropic was coined in 1972 by the Romanian Dr. Corneliu E. Giurgea,[3][4] derived from the Greek words νους nous, or "mind," and τρέπειν trepein meaning "to bend/turn". Nootropics are thought to work by altering the availability of the brain's supply of neurochemicals (neurotransmitters, enzymes, and hormones), by improving the brain's oxygen supply, or by stimulating nerve growth.

Nootropics vs. cognitive enhancers

Cognitive enhancers are drugs, supplements, nutraceuticals, and functional foods that enhance attentional control and memory.[5][6] Nootropics are cognitive enhancers that are neuroprotective or extremely nontoxic. Nootropics are by definition cognitive enhancers, but a cognitive enhancer is not necessarily a nootropic.

Giurgea's Nootropic Criteria:

  1. Enhances learning and memory.
  2. Enhance learned behaviors under conditions which are known to disrupt them. Example: hypoxia (oxygen deficiency).
  3. Protect the brain from physical or chemical injury.
  4. Enhance the tonic cortical/subcortical control mechanisms
  5. Exhibit few side effects and extremely low toxicity, while lacking the pharmacology of typical psychotropic drugs (motor stimulation, sedation etc.).

Since Giurgea's original criteria were first published, there has been little agreement as to what truly constitutes a nootropic compound. The most well defined criteria to date was established by Skondia in 1979. Skondia utilizes a metabolic approach, taking into account the pharmacological mode of action.

Skondia's Nootropic Criteria:

I. No direct vasoactivity

A. No vasodilation
B. No vasoconstriction

II. EEG activity: No change in basic rhythm

A. Quantitative EEG: Increased power spectrum (beta 2 and alpha)
B. Qualitative EEG: Decreased delta waves and cerebral suffering

III. Must pass blood-brain barrier

A. Under normal conditions
B. Under pathological conditions

IV. Must show metabolic activity in:

A. Animal brain metabolism
1. Molecular
2. Physiopathological
B. Human brain metabolism (clinical evaluation)
1. A-V differences
a. Increased extraction quotients of O2
b. Increased extraction quotients of glucose
c. Reduced lactate pyruvate ratio
2. Regional cerebral metabolic rates (rCMR)
a. Increased ICMR of O2
b. Increased rCMR of glucose
3. Regional cerebral blood flow: Normalization

V. Minimal side effects

VI. Clinical trials must be conducted with several rating scales designed to objectify metabolic cerebral improvement.

Availability and prevalence

At present, there are several drugs on the market that improve memory, concentration, and planning, and reduce impulsive behavior. Many more are in different stages of development.[7] The most commonly used class of drug is stimulants.[8]

These drugs are used primarily to treat people with cognitive or motor function difficulties attributable to such disorders as Alzheimer's disease, Parkinson's disease, Huntington's disease and ADHD. However, more widespread use is being recommended by some researchers.[9] These drugs have a variety of human enhancement applications as well, and are marketed heavily on the Internet. Nevertheless, intense marketing may not correlate with efficacy; while scientific studies support some of the claimed benefits, it is worth noting that not all of the claims from certain nootropics suppliers have been formally tested.

In academia, modafinil has been used to increase productivity, although its long-term effects have not been assessed in healthy individuals.[7] Stimulants such as methylphenidate are being used on college campuses, and by an increasingly younger group.[7] One survey found that 7% of students had used stimulants for a cognitive edge in the past year, and on some campuses the number is as high as 25%.[8]


The main concern with pharmaceutical drugs is adverse effects, and these concerns apply to cognitive-enhancing drugs as well. Cognitive enhancers are often taken for the long-term when little data is available.[7]

Dr. Corneliu E. Giurgea originally coined the word nootropics for brain-enhancing drugs with very few side-effects. Racetams are sometimes cited as an example of a nootropic with few side-effects and a wide therapeutic window.[10] In the United States, unapproved drugs or dietary supplements do not have to have safety or efficacy approval before being sold.[11]



The word nootropic was coined upon discovery of the effects of piracetam, developed in the 1960s.[12] Although piracetam is the most commonly taken nootropic,[12] (depending on one's definition of nootropic, which can sometimes include more popular substances such as caffeine and nicotine) there are many relatives in the family that have different potencies and side-effects. Studies of the racetams have revealed that these structurally similar compounds often act via different mechanisms. These other common racetams include pramiracetam, oxiracetam, and aniracetam. Their mechanisms of action are not fully understood, however, piracetam and aniracetam are known to act as positive allosteric modulators of AMPA receptors. They also appear to modulate acetylcholinergic systems.[13] Although aniracetam and nebracetam show affinity for muscarinic receptors, only nefiracetam shows it at the nanomolar range. Racetams have been called "pharmacologically safe" drugs.[10]

Vitamins and supplements

  • B Vitamins—may influence cognitive function through an effect on methylation and homocysteine levels, as excess homocysteine has been associated with cognitive impairment and the B vitamins work to reduce homocysteine.[14] However, although epidemiological evidence shows an association, two studies did not find B vitamin supplementation improves cognitive function, and another that found an association was criticized.[15] In 2008 a systematic review of trials found "little evidence of a beneficial impact" from supplements on cognitive function later in life.[16] A randomized, placebo-controlled trial in 168 70 year olds with mild cognitive impairment showed that a mix of B vitamins slowed the rate of brain atrophy; the slowing was related to a decrease in homocysteine levels.[17]
  • Omega-3—linked to the maintenance of brain function. A study done in Norway[18] demonstrated a potential link between Omega-3 consumption during pregnancy and child intelligence test scores.[19] A cross-sectional population-based study of 1,613 subjects found an association between PUFA intake and decreased risk for impairment of cognitive function & cognitive speed.[20]
  • Isoflavones—may be related to cognitive function.[21] A double-blind, placebo-controlled study showed improvement in spatial working memory after administration of an isoflavone combination containing daidzein, genistein & glycitin.[22] In a randomized, double-blind, placebo-controlled study of older, non-demented men & women, soy isoflavone supplementation improved performance on 6 of 11 cognitive tests, including visual-spatial memory and construction, verbal fluency and speeded dexterity; unexpectedly, the placebo group performed better on 2 tests of executive function.[23]
  • Vitamin D—has positive effects on cardiovascular health and may have positive effects on cognitive function separately; the active form of Vitamin D seems to be involved in brain development and in adult brain function. In particular, metabolic pathways for Vitamin D in the hippocampus and cerebellum have been found. Epidemiological data show that higher Vitamin D levels (>20 ng/mL or 50nmol/L) are associated with better cognitive function, but do not seem to be associated with better memory performance.[24]
  • A 2007 survey of online databases for herbs used in traditional herbal medicine to treat cognitive decline - without any proof of safety or efficacy - found over 150 plant species, such as Ginkgo biloba.[25]


Dopaminergics are substances that affect the neurotransmitter dopamine or the components of the nervous system that use dopamine. Attributable effects of dopamine are enhancement of attention, alertness, and antioxidant activity. Dopamine is the primary activity of stimulants like methylphenidate (Ritalin) or amphetamine. Dopaminergic nootropics include dopamine synthesis precursors, dopamine reuptake inhibitors, monoamine oxidase inhibitors, and other compounds:


Stimulants are often seen as smart drugs, but may be more accurately termed productivity enhancers. Some stimulants can enhance cognition and memory in some people, but cause psychosis in others.[citation needed] They generally have a very substantial side-effect profile and are not considered classical "nootropic" drugs. These typically improve concentration and a few areas of cognitive performance, but only while the drug is still in the blood. Some scientists recommend widespread use of stimulants such as methylphenidate and amphetamines by the general population to increase brain power.[8][35]

Concentration and memory enhancement

The nootropics in this section are purported or shown to enhance concentration or the recollection and formation of memories.


Cholinergics are substances that affect the neurotransmitter acetylcholine or the components of the nervous system that use acetylcholine. Acetylcholine is a facilitator of memory formation. Increasing the availability of this neurotransmitter in the brain may improve these functions. Cholinergic nootropics include acetylcholine precursors and cofactors, and acetylcholinesterase inhibitors:

GABA blockers

The GABAA α5 receptor site has recently displayed memory improvements when inverse agonized.

  • α5IA—α5 inverse agonist. A number of α5IA analogues exist that, like α5IA, selectively and partially agonize some GABA receptor subtypes while inverse agonizing others, which may provide a nootropic effect without the associated anxiogenic effects of general GABA inverse agonism.
  • Suritozole—α5 partial inverse agonist

Glutamate activators

The AMPA transmitter and the AMPA receptors are currently being researched, and there are signs that significant memory improvement and possible alertness enhancement may occur when agonized. The drug class for AMPA system modulation is called Ampakines. Although there are many Ampakines currently in-research, those mentioned here are significantly notable, and/or show reasonable signs of coming to market.

Some racetams have shown this activity, such as aniracetam

  • CX-717—pending FDA approval for memory-impairing illnesses
  • IDRA-21—believed to improve memory by significantly enhancing long-term potentiation but used only in animals; incredibly potent
  • LY-503,430—under development for Parkinson's but showing increase in BDNF, specifically in areas of memory and higher cognitive skills


Cyclic adenosine monophosphate is a secondary messenger that, if increased, has shown memory improvements. One common method is by decreasing the activity of phosphodiesterase-4, an enzyme that breaks down cAMP. Typical effects include wakefulness and memory enhancement.

  • Propentofylline—nonselective phosphodiesterase inhibitor with some neuroenhancement
  • Rolipram—PDE4 inhibitor, shows alertness enhancement, long term memory improvement and neuroprotection
  • Mesembrine—PDE4-inhibitor with possible serotonergic activity


α2A receptors are concentrated heavily in the prefrontal cortex and the locus coeruleus, with the potential to improve attention abilities via modulating post-synaptic α2A receptors in the prefrontal cortex.[42]

  • Guanfacine is an α2A receptor agonist, FDA approved for and frequently used to treat ADHD symptoms.[43][44] Studies have shown guanfacine to strengthen working memory, reduce distractibility, improve response inhibition, increase regional cerebral blood flow, reduce locomotor hyperactivity, and improve attentional control in animal models, as well as enhance memory function in humans.[45] Another study found no effect on healthy male adult's executive functions and working memory, and small decrements on 2 tasks relating to the sedative effect of guanfacine.[46]


Serotonin is a neurotransmitter with various effects on mood and possible effects on neurogenesis. Serotonergics are substances that affect the neurotransmitter serotonin or the components of the nervous system that use serotonin. Serotonergic nootropics include serotonin precursors and cofactors, and serotonin reuptake inhibitors:

Anti-depression, adaptogenic (antistress), and mood stabilization

Stress (specifically elevated levels of circulating corticosteroids) has been associated with the cognitive deficits seen in human aging.[58] Depression and depressed mood negatively affect cognitive performance.[citation needed] It is reasoned that counteracting and preventing depression and stress may be an effective nootropic strategy.[citation needed] The term adaptogen applies to most herbal anti-stress claims.[citation needed]

The substances below may not have been mentioned earlier on the page:

  • Beta blockers—evidence from controlled trials spanning 25 years supports the claim that beta-blockers are effective for reducing anxiety, likely through peripheral blockade of beta-receptors; most data comes from studies of generalized anxiety and acute stress.[59]
  • Lemon Balm—displays adaptogen properties; in rats it has been shown to possess GABA transaminase inhibitor activity[60] and in homogenates of human cerebral cortical cell membranes possesses activity at acetylcholine receptors.[61] In a randomized, double-blind, placebo-controlled study of 18 healthy volunteers, 600 mg of 'Melissa officinalis' extract attenuated volunteers' response to a laboratory-induced stress test 1 hour after administration; 300 mg significantly improved speed of mathematical processing 1 hour after administration.[62]
  • Passion Flower—possible MAOI and neurotransmitter reuptake activity [citation needed]
  • Rhodiola Rosea—adaptogen; possible MAOI activity[63]
  • St John's Wort—herbal supplement approved (in Europe) to treat mild depression. Method of action is unproven but exhibits effects similar to both MAOIs and SSRIs. [citation needed] There is evidence that it may decrease the effectiveness of methylphenidate treatment.[64]
  • Ginseng (including Siberian ginseng)—adaptogenic effects shown[citation needed]
  • Sutherlandia frutescens—possible anti-inflammatory, reducing pain from those illnesses [citation needed]
  • Kava—anxiolytic herb[citation needed]
  • Tea—contains many different adaptogens[citation needed]
  • Theanine—GABAergic activity producing relaxation, also increases brain serotonin and dopamine levels[citation needed]
  • Grape seed extract—has shown some efficacy in reducing bodily stress[citation needed]
  • Adafenoxate—possible anxiolytic effect[citation needed]
  • Phenibut GABA receptor agonist excerting anxiolytic effects
  • Picamilon GABA prodrug which excerts anxiolytic effects by releasing GABA and niacin in the CNS.
  • Valerian—possible anxiolytic effect through agonism at GABA-A receptors[citation needed]
  • Butea frondosa—possible anxiolytic effect[65]
  • Gotu Kola—adaptogen and anxiolytic [citation needed]
  • Foti—adaptogen; possible MAOI activity [citation needed]
  • Panax ginseng—Multiple randomized, placebo-controlled studies in healthy volunteers have been performed, results include increases in accuracy of memory, speed in performing attention tasks and improvement in performing difficult mental arithmetic tasks, as well as reduction in fatigue and improvement in mood.[66]
  • Many Chinese herbs such as Polygala tenuifolia, Acorus gramineus and Huperzia serrata.[67]
  • Bacopa monnieri[68]
  • Tulsi (Ocimum sanctum, sweet holy basil)[69]

Blood flow and metabolic function

Brain function is dependent on many basic processes such as the usage of ATP, removal of waste, and intake of new materials. Improving blood flow or altering these processes can benefit brain function. The list below contains only vasodilators that have shown at least probable mental enhancement.

  • Blessed Thistle—increases blood circulation, improving memory [citation needed]
  • Coenzyme q-10—antioxidant; increases oxygen usage by mitochondria
  • Creatine—protects ATP during transport
  • Lipoic acid—improves oxygen usage and antioxidant recycling, possibly improving memory
  • Pyritinol—Drug similar to B vitamin Pyridoxine
  • Picamilon—GABA activity and blood flow improver
  • Ginkgo biloba—vasodilator. Acts as an NRI.[70] A double-blind, placebo-controlled trial in young healthy females showed an improvement in short-term memory performance 1 hour after administration of a 600 mg dose.[71] An analysis of 29 placebo-controlled RCTs showed that "there is consistent evidence that chronic administration improves selective attention, some executive processes and long-term memory for verbal and non-verbal material."[72] A double-blind, placebo-controlled study in 20 young healthy volunteers showed a dose-dependent improvement in speed-of-attention following administration of 240 mg and 360 mg of Ginkgo extract, effects were measured 2.5h after administration and persisted at least until 6h; various other time- and dose-specific changes (some positive, some negative) in other areas were observed.[73]
  • Vinpocetine— is reported to have cerebral blood-flow enhancing[74] and neuroprotective effects,[75] and is used as a drug in Eastern Europe for the treatment of cerebrovascular disorders and age-related memory impairment.[76] Also shown to inhibit voltage-sensitive Na+ channels—however, through a similar mechanism to reserpine, Vinpocetine may temporarily deplete the monoamines serotonin, dopamine and norepinephrine by inhibiting VMAT, thus preventing them from reaching the synapse.[77] Vinpocetine may therefore induce or exacerbate depressive symptoms as an adverse effect. However, this effect tends to be reversible upon cessation of Vinpocetine administration, with full remission typically occurring within 3–4 weeks. Vinpocetine has been identified as a potent anti-inflammatory agent that might have a potential role in the treatment of Parkinson's disease and Alzheimer's disease.[78][79]
  • Vincamine—increases blood circulation (vasodilator) and metabolism in the brain; related to vinpocetine; used in sustained release.
  • Nicergoline—an ergot derivative used to treat senile dementia and other disorders with vascular origins; it has been found to increase mental agility and enhance clarity and perception; it decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells; it has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.[80]

Experimental histamine antagonists

The H3-receptor decreases neurotransmitter release: histamine, acetylcholine, norepinephrine, serotonin. Thus, H3-receptor-antagonists increases cognition and wakefulness.

  • Ciproxifan—produces wakefulness and attentiveness in animal studies, and produced cognitive enhancing effects without prominent stimulant effects at relatively low levels of receptor occupancy, and pronounced wakefulness at higher doses.[81]
  • A-349,821—It has nootropic effects in animal studies.[82]
  • ABT-239 - strong H3 receptor inverse agonist that is more active than ciproxifan, but its investigation into human use was dropped after it was discovered to cause QT prolongation in subjects

Nerve growth stimulation and brain cell protection

Nerves are necessary to the foundation of brain communication and their degeneracy, underperformance, or lacking can have disastrous results on brain functions. Antioxidants may prevent oxidative stress and cell death, therefore exerting a neuroprotective effect.

Direct hormones

These are hormones that have activity not necessarily attributable to another specific chemical interaction, but have shown effectiveness. Only specific nootropic effects are stated.

  • Vasopressin—memory hormone that improves both memory encoding and recall. Desmopressin (1-desamino-8-D-arginine vasopressin, DDAVP) was given to 17 children with attention & learning disorders daily for 10 days in a placebo-controlled, randomized, double-blind study; memory & learning were improved compared with placebo; the same study failed to find similar benefits after administration of a single dose.[91]
  • Pregnenolone—increases neurogenesis
  • Orexin—Significant wakefulness promoter

Secondary enhancers

These are substances that by themselves may not improve brain function, but may have benefits for those who lack them (in the case of hormones) or may alter the balance of neurotransmitters.

Unknown enhancement

Other agents purported to have nootropic effects but do not (yet) have attributable mechanisms or clinically significant effects (but may upon refinement of administration) are listed below.

Nootropics with proven or purported benefits:

  • Bacopa monniera (Brahmi) — Shown to possess adaptogenic properties and enhance memory and concentration.[92] Folk use in Ayurvedic medicine purports "enhancement of curiosity"; Brahmi rasayana has been shown to improve learning and memory in mice[93]
  • Clitoria ternatea (Shankhpushpi) — In traditional Ayurvedic medicine, it has been used for centuries as a memory enhancer, nootropic, antistress, anxiolytic, antidepressant, anticonvulsant, tranquilizing and sedative agent.
  • Fipexide—drug for Dementia
  • Gerovital H3—famous alleged anti-aging mixture, most effects disproven but some mind enhancement shown
  • Sulbutiamine—fat soluble vitamin B1 derivative—caused mice to perform better on operant conditioning tests[94] and object recognition tests[95]
  • Royal Jelly—Increases brain cell growth and diversity, only demonstrated in-vitro, improbable in-vivo (it has been reported to stimulate the growth of glial cells[96] and neural stem cells in the brain.[97])
  • Curcumin—significant in-vitro activity, but in-vivo activity limited by low bioavailability unless accompanied by ingestion of piperine


Although not nootropics from the standpoint of cognitive enhancement, adaptogens are plants that help the body adapt to stress. By creating an environment whereby stress is reduced, cortisol (a degenerative hormone) release is impaired. These substances have been linked to better cognitive function, but may not be the cause. See correlation does not imply causation.

Examples of adaptogens are plants like the ayurvedic "Holy Basil" or "Tulsi" which is commonly found in nootropic supplements like excelerol.[92]

Other nootropics

Other substances sometimes classified as nootropics include mexidol, hydergine,[10] noopept, selank, semax and bifemelane.

See also

Brain and neurology

Thought and thinking (what nootropics are used for)



  1. Dorlands Medical Dictionary.
  2. Lanni C, Lenzken SC, Pascale A, et al. (March 2008). Cognition enhancers between treating and doping the mind. Pharmacol. Res. 57 (3): 196–213.
  3. Gazzaniga, Michael S. (2006). The Ethical Brain: The Science of Our Moral Dilemmas (P.S.), 184, New York, N.Y: Harper Perennial.
  4. Giurgea C (1972). [Pharmacology of integrative activity of the brain. Attempt at nootropic concept in psychopharmacology] ("Vers une pharmacologie de l'active integrative du cerveau: Tentative du concept nootrope en psychopharmacologie"). Actual Pharmacol (Paris) 25: 115–56.
  5. Dorlands Medical Dictionary.
  6. Lanni C, Lenzken SC, Pascale A, et al. (March 2008). Cognition enhancers between treating and doping the mind. Pharmacol. Res. 57 (3): 196–213.
  7. 7.0 7.1 7.2 7.3 (December 2007). Professor's little helper. Nature 450 (7173): 1157–9.
  8. 8.0 8.1 8.2 "Towards responsible use of cognitive-enhancing drugs by the healthy" in Nature: International Weekly Journal of Science. URL accessed on December 2008.
  9. Smart Drugs and Should We Take Them?. Dolan DNA Learning Center. URL accessed on 2012-11-04.
  10. 10.0 10.1 10.2 Malik R, Sangwan A, Saihgal R, Jindal DP, Piplani P (2007). Towards better brain management: nootropics. Curr. Med. Chem. 14 (2): 123–31.
  11. Goldman P (2001). Herbal medicines today and the roots of modern pharmacology. Ann. Intern. Med. 135 (8 Pt 1): 594–600.
  12. 12.0 12.1 McDaniel, M.A., Maier, S.F., and Einstein, G.O. (2002). Brain-Specific Nutrients: A Memory Cure?. Psychological Science in the Public Interest 19 (11): 957–75.
  13. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C (2002). Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr. Pharm. Des. 8 (2): 125–38.
  14. Selhub J, Bagley L, Miller J, Rosenberg I (2000). B vitamins, homocysteine, and neurocognitive function in the elderly. American Journal of Clinical Nutrition 71 (2): 614S–620s.
  15. Huskisson E, Maggini S, Ruf M (2007). The influence of micronutrients on cognitive function and performance. J. Int. Med. Res. 35 (1): 1–19.
  16. Jia X, McNeill G, Avenell A (August 2008). Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A systematic review of randomized controlled trials. J Hum Nutr Diet 21 (4): 317–36.
  17. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H (September 2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.. PLoS ONE 8 (5(9)).
  18. Pediatrics. 2003 Jan;111(1):e39-44
  19. Prevention [0032-8006] Chillot yr.2004 vol.56 iss.1 pg.122 -9
  20. Kalmijn S, van Boxtel MP, Ocké M, Verschuren WM, Kromhout D, Launer LJ (January 2004). Dietary intake of fatty acids and fish in relation to cognitive performance at middle age.. Neurology 62 (2): 275–80.
  21. Wong MC, Emery PW, Preedy VR, Wiseman H (October 2008). Health benefits of isoflavones in functional foods? Proteomic and metabonomic advances. Inflammopharmacology 16 (5): 235–9.
  22. Thorp AA, Sinn N, Buckley JD, Coates AM, Howe PR (November 2009). Soya isoflavone supplementation enhances spatial working memory in men.. Br J Nutr 102 (9): 1348–54.
  23. Gleason CE, Carlsson CM, Barnet JH, Meade SA, Setchell KD, Atwood CS, Johnson SC, Ries ML, Asthana S (January 2009). A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age Ageing 38 (1): 86–93.
  24. Buell JS, Scott TM, Dawson-Hughes B, Dallal GE, Rosenberg IH, Folstein MF, Tucker KL (Aug 2009). Vitamin D is associated with cognitive function in elders receiving home health services.. J Gerontol A Biol Sci Med Sci. 64 (8): 888–95.
  25. Adams M, Gmünder F, Hamburger M (September 2007). Plants traditionally used in age related brain disorders--a survey of ethnobotanical literature. J Ethnopharmacol 113 (3): 363–81.
  26. (Dec 1996). Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons.. Brain Res 743 (1-2): 278–83.
  27. (Oct 1997). L-DOPA neurotoxicity is mediated by glutamate release in cultured rat striatal neurons.. Brain Res 771 (1): 159–62.
  28. (Nov 2003). Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells.. Biochem Pharmacol 66 (9): 1787–95.
  29. (Sep 1981). Biosynthesis of biopterin: adrenergic cyclic adenosine monophosphate-dependent inhibition in the pineal gland.. Science 213 (4512): 1129–31.
  30. 30.0 30.1 (Mar 2009). Monoamine oxidase inhibition by Rhodiola rosea L. roots.. J Ethnopharmacol 122 (2): 397–401.
  31. Giménez R, Raïch J, Aguilar J (November 1991). Changes in brain striatum dopamine and acetylcholine receptors induced by chronic CDP-choline treatment of aging mice. British Journal of Pharmacology 104 (3): 575–8.
  32. Teather LA, Wurtman RJ (2005). Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learning & Memory 12 (1): 39–43.
  33. includeonly>"Supplement naturally boosts ageing brain power", Sydney Morning Herald, 2008-02-25. Retrieved on 2009-07-28.
  34. Silveri MM, Dikan J, Ross AJ, et al. (November 2008). Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR in Biomedicine 21 (10): 1066–75.
  35. includeonly>Szalavitz, Maia. "Popping Smart Pills: The Case for Cognitive Enhancement - TIME", Time, 2009-01-06. Retrieved on 2010-05-20.
  36. Heishman SJ, Kleykamp BA, Singleton EG (2010-06). Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl). 210 (4): 453–69.
  37. Rogers, P. (2007). Caffeine, mood and mental performance in everyday life.. Psychology Today 32 (1): 84–89.
  38. Kiefer, I. (2007). Brain Food. Scientific American Mind 18 (5): 58–63.
  39. Tang, L., Wang, R., Tang, X. (2005). Effects of huperzine A on secretion of nerve growth factor in cultured rat cortical astrocytes and neurite outgrowth in rat PC12 cells. Acta Pharmacologica Sinica 26 (6): 673–678.
  40. (2006). A molecular link between the active component of marijuana and Alzheimer's disease pathology.. Mol Pharm 3 (6): 773–7.
  41. Wen Jiang; Yun Zhang; Lan Xiao; Jamie Van Cleemput; Shao-Ping Ji; Guang Bai; Xia Zhang (2005-11-01). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. Journal of Clinical Investigation 115 (11): 3104–16.
  42. (2008). Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment 4 (2): 389–403.
  43. Compositions and Methods for Treating Cognitive Disorders. United States Patent Application 20090221610.
  44. includeonly>"Shire Receives FDA Approvable Letter For INTUNIV (guanfacine) ER, A Nonstimulant ADHD Treatment", Medical News Today, 24 June 2007.
  45. (2005). Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behavioral and Brain Functions 1 (1): 2.
  46. (2005). Lack of effects of guanfacine on executive and memory functions in healthy male volunteers. Psychopharmacology 182 (2): 205–13.
  47. Pyridoxine, regardless of serotonin levels, increases production of 5-hydroxytryptophan in rat brain.. Arch Med Res 35 (4): 271–4.
  48. (Mar 1988). Dietary pyridoxine interaction with tryptophan or histidine on brain serotonin and histamine metabolism.. Pharmacol Biochem Behav 29 (3): 559–64.
  49. (Oct 2008). Review on plants with CNS-effects used in traditional South African medicine against mental diseases.. J Ethnopharmacol 119 (3): 513–37.
  50. (Jun 2006). Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity.. Biochem Biophys Res Commun 344 (2): 688–95.
  51. (Jul 2005). The effects of curcumin on depressive-like behaviors in mice.. Eur J Pharmacol 518 (1): 40–6.
  52. (Jan 2010). Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases.. Bioorg Med Chem Lett 20 (2): 537–40.
  53. (Mar 2010). beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO).. Food Chem Toxicol 48 (3): 839–45.
  54. 54.0 54.1 DOI:10.1038/mp.2009.80
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand
  55. Kasper S, McEwen BS (2008). Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 22 (1): 15–26.
  56. Invernizzi R, Pozzi L, Garattini S, Samanin R (March 1992). Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology 31 (3): 221–7.
  57. ( Stablon, Coaxil ) and the dopamine D(2) and D(3) receptors. Tianeptine. URL accessed on 2010-08-13.
  58. Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ (May 1994). Basal cortisol levels and cognitive deficits in human aging.. J Neurosci. 14 (5pt1): 2893–903.
  59. Tyrer P (January 1992). Anxiolytics not acting at the benzodiazepine receptor: beta blockers.. Prog Neuropsychopharmacol Biol Psychiatry 16 (1): 17–26.
  60. Awad, R.; Levac, D.; Cybulska, P.; Merali, Z.; Trudeau, V.L.; Arnason, J.T. (September 2007). Effects of traditionally used anxiolytic botanicals on enzymes of the γ-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 85 (9): 933–42.
  61. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E (February 2000). CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol. 69 (2): 105–14.
  62. Kennedy DO, Little W, Scholey AB (Jul-Aug 2004). Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med. 66 (4): 607–13.
  63. Panossian A., Wikman G."Evidence based efficacy of adaptogens in fatigue" Planta Medica 2009 75:9
  64. PMID 17254717 (PMID 17254717)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
  65. Soman I, Mengi SA, Kasture SB (September 2004). Effect of leaves of Butea frondosa on stress, anxiety, and cognition in rats. Pharmacol. Biochem. Behav. 79 (1): 11–6.
  66. Kennedy DO, Wightman EL (Jan 2011). Herbal extracts and phytochemicals: plant secondary metabolites and the enhancement of human brain function.. Adv Nutr. 2 (1): 32–50.
  67. (August 2011). Are Herbal Compounds the Next Frontier for Alleviating Learning and Memory Impairments? An Integrative Look at Memory, Dementia and the Promising Therapeutics of Traditional Chinese Medicines. Phytotherapy Research 25 (8): 1105–1118.
  68. (July 2010). DoesBacopa monnieriImprove Memory Performance in Older Persons? Results of a Randomized, Placebo-Controlled, Double-Blind Trial. The Journal of Alternative and Complementary Medicine 16 (7): 753–759.
  69. (October–December 2009). The science behind sacredness of Tulsi (Ocimum sanctum Linn.). Indian journal of physiology and pharmacology 53 (4): 291–306.
  70. (Jul 2009). Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment.. Pharmacological Research 60 (1): 68–73.
  71. Hindmarch I (1986). [Activity of Ginkgo biloba extract on short-term memory].. Presse Med 15 (31): 1592–94.
  72. Kaschel R (2009). Ginkgo biloba: specificity of neuropsychological improvement--a selective review in search of differential effects.. Hum Psychopharmacol 24 (5): 345–70.
  73. Kennedy DO, Scholey AB, Wesnes KA (2000). The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers.. Psychopharmacology (Berl) 151 (4): 416–23.
  74. Szilágyi G, Nagy Z, Balkay L, et al. (2005). Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study. Journal of the Neurological Sciences 229-230: 275–84.
  75. Dézsi L, Kis-Varga I, Nagy J, Komlódi Z, Kárpáti E (2002). [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke]. Acta Pharmaceutica Hungarica 72 (2): 84–91.
  76. (2002). Vinpocetine. Monograph. Alternative Medicine Review 7 (3): 240–3.
  77. (Aug 2001). Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings.. Brain Res 909 (1-2): 59–67.
  78. (2010). Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.. Proceedings of the National Academy of Sciences of the United States of America 107 (21): 9795–800.
  79. (2010). Vinpocetine as a potent antiinflammatory agent.. Proceedings of the National Academy of Sciences of the United States of America 107 (22): 9921–2.
  80. Fioravanti M, Flicker L (2001). Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev (4): CD003159.
  81. Le S, Gruner JA, Mathiasen JR, Marino MJ, Schaffhauser H (June 2008). Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. J. Pharmacol. Exp. Ther. 325 (3): 902–9.
  82. (2004). Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochemical pharmacology 68 (5): 933–45.
  83. Kolotushkina EV, Moldavan MG, Voronin KY, Skibo GG (2003). The influence of Hericium erinaceus extract on myelination process in vitro. Fiziol Zh 49 (1): 38–45.
  84. Mori K, Obara Y, Hirota M, et al. (September 2008). Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol. Pharm. Bull. 31 (9): 1727–32.
  85. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T (March 2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research 23 (3): 367–72.
  86. The Way SAMe Works
  87. (November 2002). Role of S-adenosyl-L-methionine in the treatment of depression: A review of the evidence. The American journal of clinical nutrition 76 (5): 1158S–1161S.
  88. glutathione.
  89. (June 2002). Medications for dementia: New drugs, mechanisms are coming for Alzheimer's disease. The Journal of Family Practice 1 (6)., which cites:
    includeonly>"OSHU Researchers Investigate Substance Derived From Amazon Rainforest Plant as Possible treatment For Alzheimer's Disease", Oregon Health & Science University, March 2, 2000. “Researchers at OHSU are interested in a particular extract, derived from the bark of the vine, called PTI-00703. It has been shown to stop the formation of, and break up beta-amyloid deposits in both a test tube and animal models.”
  90. (1998). Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America 95 (14): 8268–8273.
  91. Hamburger-Bar R, Eisenberg J, Belmaker RH (Jan-Feb 1987). Animal and clinical studies of vasopressin effects on learning and memory.. Isr J Med Sci. 23 (1-2): 12–8.
  92. 92.0 92.1 Singh, H.K. and Dhawan, B.N. (1 September 1997). Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn. (Brahmi). Indian Journal of Pharmacology 29 (5): 359–65.
  93. Joshi H, Parle M (March 2006). Brahmi rasayana improves learning and memory in mice. Evid Based Complement Alternat Med 3 (1): 79–85.
  94. Micheau J, Durkin TP, Destrade C, Rolland Y, Jaffard R (1985). Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav 23 (2): 195–8.
  95. Bizot JC, Herpin A, Pothion S, Pirot S, Trovero F, Ollat H (2005). Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task. Prog Neuropsychopharmacol Biol Psychiatry 29 (6): 928–35.
  96. (April 2005). Oral administration of royal jelly facilitates mRNA expression of glial cell line-derived neurotrophic factor and neurofilament H in the hippocampus of the adult mouse brain. Bioscience, Biotechnology, and Biochemistry 69 (4): 800–805.
  97. (October 2007). Royal jelly and its unique fatty acid, 10-hydroxy-trans-2-decenoic acid, promote neurogenesis by neural stem/progenitor cells in vitro. Biomedical research (Tokyo, Japan) 28 (5): 261–266.

External links

This page uses Creative Commons Licensed content from Wikipedia (view authors).